• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

The Market and Potential for Molecular Point of Care Diagnostic Tests

$3,995.00 – $7,900.00

Clear
SKU: KLI15582179 Categories: Diagnostics Market Research, Point-of-Care Diagnostics Pages: 280
  • Description
  • Table of Contents
  • Latest reports

Description

THIS REPORT HAS A NEWER VERSION AVAILABLE: https://kaloramainformation.com/product/2021-molecular-point-of-care/

 

Among the various technologies and products of the global in vitro diagnostics (IVD) market, molecular diagnostics performed at the point of care or near the patient are regarded as a leading expansion market. Molecular point-of-care (POC) diagnostics are able to improve the sensitivity and specificity of existing near-patient and rapid tests and also expand the diagnostic capabilities at points of care such as hospital critical care units, physician offices, outpatient clinics, and community health posts in the developing world. Existing POC diagnostics range from urinalysis dipsticks performed in physician office laboratories (POLs) through rapid infectious disease tests used to quickly diagnose admitted patients.
The Definitive Market Research Study on Molecular Point of Care
There have been many projections made about molecular point care.  This report provides consensus market views and realistic estimates for this novel field.  Kalorama Information produced two definitive market studies of this market in 2013, prior to significant product development, and 2016 as the first products – Alere i, BioFire Film Array, and cobas Liat appeared on the scene.  Now, with more market track records and approvals, mPOC products competing with traditional systems, Kalorama has updated its findings with the latest information.  Who is leading?  Where is investment in mPOC systems?  Who has products in development?  What companies are lagging?   What can we expect in the future.  This report answers these questions and more.
The The Market and Potential for Molecular Point of Care Diagnostic Tests examines the major segments of molecular POC diagnostics, exploring in-depth current sales and market opportunity and providing the following market information:
  • Molecular POC Systems on the Market 
  • Molecular POC Systems in Development
  • Advantages and Disadvantages of Molecular POC
  • Molecular POC Market for Influenza Testing (2017-2023)
  • Molecular POC Market for Strep A Testing (2017-2023)
  • Molecular POC Market for RSV and Other Respiratory
  • Molecular POC Market for STD Testing [CT/NG, GBS, HSV, Others] (2017-2023)
  • Molecular POC Market for HIV (2017-2023)
  • Molecular POC Market for GI Pathogens (2017-2023)
  • Molecular POC Market for HAIs (2017-2023)
  • Other Molecular POC (2017-2023)
  • Investments in Decentralized Molecular Diagnostics Companies (2014-2017)
  • Potential Entrants into Molecular POC Diagnostics (Vendor, Current Platform[s], Primary Market for Platform, Assay Menu, Applicable Tech)
  • Retail Clinics and Other Walk-ins: Game Changers in Healthcare
 Profiled companies include those with clinical molecular diagnostic systems applicable to POC testing markets; molecular diagnostic systems applicable to hospital lab molecular testing; development-stage molecular diagnostic systems for decentralized testing; molecular diagnostic products for use primarily in emerging markets of the developing world and for field testing; companies with original equipment manufacturer (OEM) platforms and component technologies that could be featured in the molecular POC diagnostics market; and other companies that have been involved in molecular POC diagnostics through investment, collaborative research or technology development that could allow them to enter the market. Companies profiled include:
The market introduction of POC diagnostics or tests (POCTs) often follows a period of technological maturation or refinement of an existing laboratory diagnostic modality or platform. One of the major enabling technologies for POC testing with molecular diagnostics is real-time polymerase chain reaction (qPCR) testing that eliminated the need for post-amplification electrophoresis and integrated detection within the same instrument that performed amplification. Advances and innovations in microfluidics; isothermal and other alternative amplification chemistries; test automation; primers and probes; and next-generation sequencing (NGS) methods have been the most significant to the development of decentralized molecular diagnostics. In many cases, these technologies work together to facilitate clinical molecular testing in an automated manner within a smaller device.
Who is Who in Molecular POC? – Company Coverage
Companies profiled in this report include:
  • Ahram Biosystems  
  • Akonni Biosystems  
  • Alere (Abbott)  
  •  Analytik Jena  
  • Atlas Genetics  
  • Axxin  
  • Becton, Dickinson And Company  
  • Biocartis  
  • Biomerieux  
  • Canon Biomedical  
  • Cepheid  
  •  Curetis  
  • Destina Genomics  
  • Diagnostics For All  
  • Diagnostics For The Real World  
  • Diasorin  
  • Diassess  
  • Eiken Chemical  
  • Entopsis  
  • Erba Molecular  
  • Genedrive Plc (Formerly Epistem)  
  •  Genefluidics  
  • Genepoc  
  • Genereach Biotechnology  
  • Greiner Bio-One  
  • Hai Kang Life  
  • Hain Lifescience  
  • Illumina 
  •  Immunexpress  
  • Insilixa  
  • Lucigen  
  • Mast Group  
  • Mbio Diagnostics  
  • Meridian Bioscience  
  •  Mesa Biotech  
  • Metaara Medical Technologies  
  • Micronics (Sony) 
  • MolBio  
  • MP Biomedicals  
  • Nanoivd 235
  • Nanodetection Technology  
  • Nanōmix  
  • Nanosphere (Luminex)  
  •  Optigene  
  • Orion Diagnostica  
  •  Positive Id  
  •  Pretect 
  • Qiagen  
  •  Quantumdx  
  • Quidel  
  •  Rheonix 
  • Roche Diagnostics  
  •  Scanogen  
  • Seegene 
  •  Spartan Bioscience  
  • Stat-Dx  
  • T2 Biosystems  
  •  Thermal Gradient  
  • Ubiquitome  
  • Ustar Biotechnologies  
  • Veredus Laboratories  
  • Wave 80 Bioscience 

Table of Contents

ONE: EXECUTIVE SUMMARY

MOLECULAR POINT-OF-CARE DIAGNOSTICS DEFINED

STRENGTHS AND WEAKNESS OF MOLECULAR POINT-OF-CARE TESTING

Table 1-1 Advantages of Molecular Point-of-care by Setting

Table 1-2: Disadvantages of Point-of-Care Diagnostics by Setting – Hospital POC, POL/Outpatient, Low-Resource and Developing Areas

COMPONENT TECHNOLOGIES OF MOLECULAR POINT-OF-CARE DIAGNOSTICS

Microfluidics

qPCR

Microarrays

Isothermal Amplification

Test Automation

Primers and Probes

Detection

Next-Generation Sequencing

Table 1-3: Molecular POC Products on the Market

SCOPE AND METHODOLOGY

SIZE AND GROWTH OF THE MARKET

Figure 1-1: Molecular Point of Care Market, 2017-2023 ($ millions)

Conclusions

Table 1-4: Growth Areas for Molecular POC and Rapid Tests

TWO: WHAT IS MOLECULAR POINT-OF-CARE DIAGNOSTICS?

ADVANTAGES AND DISADVANTAGES OF MOLECULAR POINT-OF-CARE

COMMON TESTS AND ANALYTES IN POC DIAGNOSTICS

MOLECULAR DIAGNOSTICS

Real-Time PCR (qPCR)

Isothermal Amplification Methods

Microarrays

Sequencing

Common Tests and Analytes in Molecular Diagnostics

Table 2-1: Selected POCTs for the diagnosis of illnesses covered by Emergency Use Authorizations (EUAs) currently in effect

POINT-OF-CARE DIAGNOSTICS IN BRIEF

Examples of POCT settings

THREE: MOLECULAR POC SYSTEMS ON THE MARKET AND IN DEVELOPMENT

INTRODUCTION

Advances in Molecular Diagnostics

Microfluidics

Isothermal Amplification

Table 3-1: Selected Isothermal Amplification Methods and Platform Examples

Test Automation

Primers and Probes

DETECTION

Table 3-2: Selected Analyzer Platforms for Decentralized and POC Molecular Testing with Image Sensor Detectors (CCD, CMOS)

Table 3-3: Selected Analyzer Platforms for Decentralized and POC Molcular Testing with Photodiode Detectors

Table 3-4: Selected Analyzer Platforms for Decentralized and POC Molecular Testing with Electrochemical Detectors

Table 3-5: Selected Analyzer Platforms for Decentralized and POC Molecular Testing with Immunochromatographic Detection

Next-Generation Sequencing

Table 3-6: Selected NGS Platforms for Decentralized and POC Sequencing

MOLECULAR PLATFORMS AND PRODUCTS FOR DECENTRALIZED TESTING

Table 3-7: Market-Available Molecular POC Diagnostic Platforms (Vendor, Assay Menu, Planned Assays, Regulatory Status, Procedure Integration, Test Principles)

Table 3-8: Market-Available Hospital Molecular Diagnostic Platforms (Vendor, Assay Menu, Planned Assays, Regulatory Status, Procedure Integration, Test Principles)

Table 3-9: Hospital and POC Molecular Diagnostic Platforms in Development (Vendor, Assay Menu, Procedure Integration, Test Principles)

Table 3-10: Menu Expansions for Hospital and POC Molecular Platforms (Vendor, Platform, Menu Addition, Time to Results, CLIA-waiver, US/EU Availability)

Table 3-11: Market-Available Molecular Diagnostic Platforms for Emerging Markets and the Developing World (Vendor, Assay Menu, Planned Assays, Regulatory Status, Procedure Integration, Test Principles) .. 71

Table 3-12: Molecular Diagnostic Platforms in Development for Emerging Markets and the Developing World (Vendor, Assay Menu, Procedure Integration, Test Principles)

Table 3-13: Line Probe Assays and Other Molecular Lateral Flow Test Strips (Vendor, Assay Menu, Planned Assays, Regulatory Status)

Table 3-14: Potential Entrants into Molecular POC Diagnostics (Vendor, Current Platform[s], Primary Market for Platform, Assay Menu, Applicable Tech)

Table 3-15: Selected Developmental Molecular POC-Enabling Technologies and Platforms by Vendor

APPLICATIONS AND POTENTIAL APPLICATIONS FOR MOLECULAR POINT-OF-CARE

Major Testing Applications for Molecular POC Diagnostics

Hospital-Acquired Infections (HAIs)

Strep A

Respiratory Syncytial Virus (RSV)

Influenza

Other Respiratory Infections

Group B Streptococcus

Human Papillomavirus

Chlamydia and Gonorrhea

Herpes Simplex Virus

Vaginitis

Human Immunodeficiency Virus (HIV)

Tuberculosis

Hepatitis

Malaria

Other Tropical and Neglected Diseases

Gastrointestinal Infections

Bloodstream Infections (BSIs)

Pharmacogenetics

Hereditary Disease

Cancer

URGENT CARE CLINICS

Table 3-16: Urgent Care Centers vs. Retail Clinics and Physician Practices

RETAIL CLINICS

FOUR: MARKET ANALYSIS

SIZE AND GROWTH OF THE MARKET

Figure 4-1: Market Analysis, Molecular Point of Care – 2017-2023 ($ millions)

Challenges for Molecular POC

MARKET LEADERS

Abbott / Alere i

Biocartis: An Ascendant Player

Cepheid Gene Xpert and, Xpert Xpress and Xpert Omni

Roche cobas Liat

Biomerieux BioFire Film Array

MARKET BY GEOGRAPHY

Figure 4-2: Molecular Point of Care Market by Geography

MARKET ESTIMATE AND MARKET POTENTIAL BY TYPE OF DISEASE

Table 4-1: Market for Molecular POC by Test (Influenza, Strep A, RSV, Other Resp., CT/NG, GBS, HPV, HSV, TV, TB, HIV, Hep, Malaria, Tropical/Other Neglected, HAIs, Other Molecular POC)

Figure 4-3: Molecular POC Market by Category, 2017 (Flu/Resp. Vs. All Other)

Influenza

Strep A, RSV and Other Respiratory

CT/NG

HPV

HSV

HIV

Hepatitis

Malaria

Other Molecular POC Testing

FIVE: COMPANY PROFILES

AHRAM BIOSYSTEMS

AKONNI BIOSYSTEMS

ALERE (ABBOTT)

Table 5-1: Alere Revenue (2014-H1 2017)

ANALYTIK JENA

ATLAS GENETICS

AXXIN

BECTON, DICKINSON AND COMPANY

Table 5-2: Becton, Dickinson & Co. (BD) Revenue (2014-2017)

BIOCARTIS

Table 5-3: Biocartis NV Revenue (2014-2017)

BIOMERIEUX

Table 5-4: bioMérieux Revenue (2014-2017)

CANON BIOMEDICAL

CEPHEID

Table 5-5: Cepheid Revenue (2013-2016)

Molecular Healthcare-Acquired Infection (HAI) Testing

Molecular Sexual Health and Women’s Health Testing

Molecular Critical Infectious Disease Testing

Molecular Oncology/Genetics Testing

CURETIS

DESTINA GENOMICS

DIAGNOSTICS FOR ALL

DIAGNOSTICS FOR THE REAL WORLD

DIASORIN

Table 5-6: DiaSorin Revenue (2014-Q3 2017)

DIASSESS

EIKEN CHEMICAL

Table 5-7: Eiken Chemical Revenue (FY 2014-2017)

ENTOPSIS

ERBA MOLECULAR

GENEDRIVE PLC (FORMERLY EPISTEM)

Table 5-8: genedrive Revenue (FY 2014-2017)

GENEFLUIDICS

GENEPOC

GENEREACH BIOTECHNOLOGY

GREINER BIO-ONE

HAI KANG LIFE

HAIN LIFESCIENCE

ILLUMINA

Table 5-9: Illumina Revenue (FY 2014-2017)

IMMUNEXPRESS

INSILIXA

LUCIGEN

MAST GROUP

MBIO DIAGNOSTICS

MERIDIAN BIOSCIENCE

Table 5-10: Meridian Bioscience Revenue (FY 2014-2017)

MESA BIOTECH

METAARA MEDICAL TECHNOLOGIES

MICRONICS (SONY)

MOLBIO

MP BIOMEDICALS

NANODETECTION TECHNOLOGY

NANOIVD

NANŌMIX

NANOSPHERE (LUMINEX)

Table 5-11: Nanosphere Revenue (2013-2016)

OPTIGENE

ORION DIAGNOSTICA

Table 5-12: Orion Diagnostica Revenue (2014-Q3 2017)

POSITIVEID

Table 5-13: PositiveID Revenue (2014-Q3 2017)

PRETECT

QIAGEN

Table 5-14: QIAGEN Revenue (2014-Q3 2017)

HPV

Other Activities (Development, Licensing, Investment)

QUANTUMDX

QUIDEL

Table 5-15: Quidel Corporation Revenue (2013-2016)

RHEONIX

ROCHE DIAGNOSTICS

Table 5-16: Roche Diagnostics Revenue (2014-2017)

SCANOGEN

SEEGENE

Table 5-17: Seegene Revenue (2014-Q3 2017)

SPARTAN BIOSCIENCE

STAT-DX

T2 BIOSYSTEMS

Table 5-18: T2 Biosystems Revenue (2014-Q3 2017)

THERMAL GRADIENT

UBIQUITOME

USTAR BIOTECHNOLOGIES

VEREDUS LABORATORIES

WAVE 80 BIOSCIENCE

 

    Global Immunoassay Market: Trends, Technologies, and Growth Opportunities, 2025
    June 12, 2025
    Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 12th Edition
    May 13, 2025
    In Vitro Diagnostic (IVD) Trends and Market Update, 2025
    April 7, 2025
    In Vitro Diagnostics Business Outlook, 2025 (6 Issues)
    April 3, 2025

Related products

  • Placeholder image

    The U.S. Market for Interventional Radiology Products

    $3,500.00 – $7,000.00
  • Placeholder image

    Worldwide Point of Care (POC): Are Decentralized Clinical Diagnostics a Cost Drain or Revenue Driver?

    $1,500.00 – $5,990.00
  • Placeholder image

    Diagnostics for Emerging Infectious Disease Threats, Volumes I – III

    $3,995.00 – $7,990.00
  • Placeholder image

    Molecular Imaging Agents and Systems – A Market Briefing

    $995.00 – $1,990.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Global Over-the-Counter (OTC) Drug MarketsThe Market and Potential for CRISPR/Cas9 Gene Editing
Scroll to top